The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $16.60

Today's change-0.45 -2.64%
Updated September 27 12:33 PM -4GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $16.60

Today's change-0.45 -2.64%
Updated September 27 12:33 PM -4GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc down (U.S.)$0.45

Vanda Pharmaceuticals Inc is sharply lower today, dropping (U.S.)$0.45 or 2.64% to (U.S.)$16.60. Over the last five days, shares have gained 8.57% and 78.30% year to date. Shares have outperformed the S&P 500 by 21.03% during the last year.

Key company metrics

  • Open(U.S.) $16.98
  • Previous close(U.S.) $17.05
  • High(U.S.) $17.21
  • Low(U.S.) $16.57
  • Bid / Ask(U.S.) $16.59 / (U.S.) $16.60
  • YTD % change+78.30%
  • Volume408,935
  • Average volume (10-day)1,328,494
  • Average volume (1-month)1,092,792
  • Average volume (3-month)748,774
  • 52-week range(U.S.) $6.91 to (U.S.) $18.00
  • Beta1.37
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.96
Updated September 27 12:33 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.19%Sector:HealthcareIndustry:Biotechnology

Latest Company News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue36333228
Total other revenue--------
Total revenue36333228
Gross profit30272622
Total cost of revenue6667
Total operating expense41464738
Selling / general / administrative25292918
Research & development78910
Depreciation / amortization3333
Interest expense (income), net operating--------
Unusual expense (income)----0--
Other operating expenses, total--------
Operating income-5-12-15-10
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-5-12-15-9
Income after tax-5-12-15-9
Income tax, total--------
Net income-5-12-15-9
Total adjustments to net income--------
Net income before extra. items-5-12-15-9
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5-12-15-9
Inc. avail. to common incl. extra. items-5-12-15-9
Diluted net income-5-12-15-9
Dilution adjustment--------
Diluted weighted average shares43434342
Diluted EPS excluding extraordinary itemsvalue per share-0.11-0.29-0.35-0.22
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.11-0.29-0.35-0.22